drugset
drugset / Trial / NCT05387499

A Study of NP-011 in Healthy Volunteers

NCT05387499 ↗

Phase 1 Completed 64 enrolled Nexel Co., Ltd. Novotech (Australia) Pty Limited · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.

Timeline

Start
2022-06-10
Primary completion
2023-03-07
Completion
2023-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject NP-011 Protein / enzyme biologic 250 ug Intravenous
Subject NP-011 Protein / enzyme biologic 500 ug Intravenous
Subject NP-011 Protein / enzyme biologic 1000 ug Intravenous
Subject NP-011 Protein / enzyme biologic 2000 ug Intravenous
Subject NP-011 Protein / enzyme biologic 4000 ug Intravenous

Indications

myocardial infarction